AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28199556 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (CA)
Number of subjects: 640
Study 26062187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking (once a day for 4 weeks)
Number of subjects: 90
Study 26062187 — intervention group
Group type: COMPARATOR
Intervention: Captopril tablets (12.5 mg, twice a day)
Number of subjects: 90
Study 26062187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking
Number of subjects: 90
Study 26062187 — intervention group
Group type: COMPARATOR
Intervention: Captopril tablets
Number of subjects: 90
Study 24135573 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV
Number of subjects: 250
Study 24135573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 21601287 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram + placebo (MONO condition)
Number of subjects: 605
Study 21601287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-sustained release + escitalopram (COMB condition)
Number of subjects: 605
Study 21601287 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release + mirtazapine (COMB condition)
Number of subjects: 605
Study 21601287 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Bupropion + Escitalopram or Venlafaxine + Mirtazapine)
Number of subjects: 605
Study 21601287 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (Escitalopram + placebo)
Number of subjects: 605
Study 19508716 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Inventory of Psychosocial Problems (SIPP)
Number of subjects: 0
Study 19508716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SIPP usage)
Number of subjects: 0
Study 16426091 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 112
Study 16426091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 14706487 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (extended-release version)
Number of subjects: 20
Study 14706487 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory P300 topography (FC2:P4 amplitude ratio >0.5)
Number of subjects: 20
Study 11990444 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EMD and BDX
Number of subjects: 17
Study 11990444 — intervention group
Group type: COMPARATOR
Intervention: BDX alone (positive control group)
Number of subjects: 17
Study 9650731 — intervention group
Group type: EXPERIMENTAL
Intervention: Allithiamin and pantethine supplementation (1 g of allithiamin and 1.8 g of a 55%/45% pantethine/pantothenic acid compound)
Number of subjects: 6
Study 9650731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 7663539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/day estradiol patch
Number of subjects: 0
Study 7663539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/day estradiol patch
Number of subjects: 0
Study 7663539 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day oral conjugated estrogens (Premarin)
Number of subjects: 0
Study 7663539 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 2486587 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm intravenous crystalloid and prep solutions, extra body covering (Group 2)
Number of subjects: 40
Study 2486587 — intervention group
Group type: COMPARATOR
Intervention: No warm intravenous crystalloid or extra body covering (Group 1)
Number of subjects: 40
Study 2486587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 40
Study 786135 — intervention group
Group type: EXPERIMENTAL
Intervention: Anileridine
Number of subjects: 60
Study 786135 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60
Study 31625262 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES)
Number of subjects: 988
Study 31625262 — intervention group
Group type: COMPARATOR
Intervention: Alternative diagnostic approach using HbA1c and fasting plasma glucose
Number of subjects: 988
Study 28826895 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative β-blocker use
Number of subjects: 4076
Study 25552523 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance rehabilitation group
Number of subjects: 130
Study 25552523 — intervention group
Group type: COMPARATOR
Intervention: Functional rehabilitation group
Number of subjects: 130
Study 23507424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg daily for four weeks
Number of subjects: 122
Study 23507424 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg for four weeks
Number of subjects: 122
Study 23507424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg for four weeks
Number of subjects: 122
Study 23507424 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 40mg / ezetimibe 10mg for four weeks
Number of subjects: 122
Study 23507424 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40mg alone
Number of subjects: 122
Study 21087317 — intervention group
Group type: EXPERIMENTAL
Intervention: Large (1-2 mm) bovine bone mineral particles
Number of subjects: 10
Study 21087317 — intervention group
Group type: COMPARATOR
Intervention: Small (0.25-1 mm) bovine bone mineral particles
Number of subjects: 10
Study 21087317 — intervention group
Group type: COMPARATOR
Intervention: Micro-CT measurements
Number of subjects: 10
Study 21087317 — intervention group
Group type: COMPARATOR
Intervention: Histomorphometric analysis
Number of subjects: 10
Study 19614974 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural two‐alternative forced‐choice tasks
Number of subjects: 0
Study 19614974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch variation
Number of subjects: 0
Study 19614974 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) analysis of N100m
Number of subjects: 0
Study 17267530 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tutorials (6 tutorials installed on a computer in the emergency department, each lasting 10 minutes)
Number of subjects: 95
Study 17267530 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tutorials
Number of subjects: 95
Study 15482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg)
Number of subjects: 128
Study 15482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg)
Number of subjects: 128
Study 15482765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and rosiglitazone
Number of subjects: 128
Study 15482765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 11737418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal DHT and one subdermal LNG implant
Number of subjects: 43
Study 11737418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal DHT and two subdermal LNG implants
Number of subjects: 43
Study 11737418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal DHT and four subdermal LNG implants
Number of subjects: 43
Study 11737418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal DHT and oral LNG
Number of subjects: 43
Study 11737418 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal DHT only
Number of subjects: 43
Study 9050428 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment of anxiety
Number of subjects: 0
Study 9050428 — intervention group
Group type: COMPARATOR
Intervention: Control group (within-subjects controlled trial)
Number of subjects: 0
Study 7937352 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (4 pmol.kg‐1.min‐1)
Number of subjects: 10
Study 7937352 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline infusion
Number of subjects: 10
Study 31969108 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote model intervention with at-home, parent-delivered intervention and weekly video conferencing with interventionists.
Number of subjects: 30
Study 29878280 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of L-DOPA
Number of subjects: 54
Study 29878280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 28973211 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (0.5 g/kg of body weight)
Number of subjects: 111
Study 28973211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% albumin in saline)
Number of subjects: 111
Study 28973211 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg (2 infusions) in open extension
Number of subjects: 111
Study 25647278 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructive surgery
Number of subjects: 120
Study 25647278 — intervention group
Group type: COMPARATOR
Intervention: Facial defects
Number of subjects: 120
Study 22921176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 29
Study 22921176 — intervention group
Group type: COMPARATOR
Intervention: Control group participation
Number of subjects: 29
Study 21403043 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided care
Number of subjects: 850
Study 21403043 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study 18313032 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental theory manipulation
Number of subjects: 0
Study 18313032 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16441945 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 g fruit and vegetables/day
Number of subjects: 43
Study 16441945 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich drink (control)
Number of subjects: 43
Study 12829681 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary systemic therapy (PST)
Number of subjects: 0
Study 12829681 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations regarding PST regimens and techniques
Number of subjects: 0
Study 10623700 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m(2))
Number of subjects: 614
Study 10623700 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m(2) 24-hour infusion)
Number of subjects: 614
Study 10623700 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paclitaxel (135 mg/m(2)) followed by cisplatin (75 mg/m(2))
Number of subjects: 614
Study 9098913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress reduction program conducted by worksite supervisors over 1 year
Number of subjects: 5
Study 9098913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress reduction program
Number of subjects: 5
Study 1489290 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 101
Study 1489290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg + Dipyridamole 300 mg
Number of subjects: 101
Study 2418296 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (60 mg s.l.)
Number of subjects: 12
Study 2418296 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN; 20 mg s.l.)
Number of subjects: 12
Study 2418296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (10 mg i.v.)
Number of subjects: 12
Study 2418296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31455312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapy (includes oedema and scar management, splinting, movement exercises, and practice of everyday activities)
Number of subjects: 160
Study 31455312 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapy
Number of subjects: 160
Study 31455312 — intervention group
Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 160
Study 29065098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitrite (NaNO2) infusion at 240 μg/kg/h for 2 hours
Number of subjects: 28
Study 29065098 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infusion
Number of subjects: 28
Study 27880811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg)
Number of subjects: 356
Study 27880811 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (0.5 mg/kg)
Number of subjects: 356
Study 27880811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 25092547 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/day dexamethasone for 28 days followed by a 2-week taper (enhanced)
Number of subjects: 32
Study 25092547 — intervention group
Group type: COMPARATOR
Intervention: 6 mg/day dexamethasone for 10 days (conventional)
Number of subjects: 32
Study 23232787 — intervention group
Group type: EXPERIMENTAL
Intervention: Plavix
Number of subjects: 0
Study 23232787 — intervention group
Group type: COMPARATOR
Intervention: Generic clopidogrel hydrochloride
Number of subjects: 0
Study 20225326 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction radiotherapy (1 x 8 Gy)
Number of subjects: 274
Study 20225326 — intervention group
Group type: COMPARATOR
Intervention: Multiple fraction radiotherapy (6 x 4 Gy)
Number of subjects: 274
Study 20225326 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 274
Study 17660129 — intervention group
Group type: EXPERIMENTAL
Intervention: Small access appendectomy (SAA)
Number of subjects: 120
Study 17660129 — intervention group
Group type: COMPARATOR
Intervention: Conventional appendectomy (CAP)
Number of subjects: 120
Study 16222011 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal parasitemia at the first antenatal visit
Number of subjects: 275
Study 16222011 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal parasitemia at delivery
Number of subjects: 275
Study 16222011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord parasitemia
Number of subjects: 275
Study 11856793 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (target temperature, 32 degrees C to 34 degrees C, for 24 hours)
Number of subjects: 273
Study 11856793 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (standard treatment)
Number of subjects: 273
Study 11856793 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 273
Study 11856793 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 273
Study 10912975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 56
Study 10912975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7710563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 to 360 mg/day)
Number of subjects: 54
Study 7710563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 2278366 — intervention group
Group type: EXPERIMENTAL
Intervention: APA (acute parenteral alimentation)
Number of subjects: 20
Study 2278366 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% NaCl solution)
Number of subjects: 20
Study 364003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Chlorhexidine gel
Number of subjects: 30
Study 364003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31938878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca ceremonies
Number of subjects: 50
Study 31066115 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy-focused structured education programme
Number of subjects: 265
Study 31066115 — intervention group
Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 265
Study 25438821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 2
Study 25438821 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 2
Study 23615407 — intervention group
Group type: EXPERIMENTAL
Intervention: iMR imaging group
Number of subjects: 50
Study 23615407 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 21323176 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine
Number of subjects: 3292
Study 21323176 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine
Number of subjects: 3292
Study 21323176 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of DTPa-IPV/Hib
Number of subjects: 3292
Study 21323176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 3292
Study 19586144 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image challenge (trying on a bathing suit)
Number of subjects: 133
Study 19586144 — intervention group
Group type: COMPARATOR
Intervention: Control condition (evaluating a purse)
Number of subjects: 133
Study 17448442 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit cognitive associations with smoking
Number of subjects: 67
Study 17448442 — intervention group
Group type: EXPERIMENTAL
Intervention: Density of smokers in participants' social environment
Number of subjects: 67
Study 14531817 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein diet (VLPD) group (0.3 g/kg body weight/day)
Number of subjects: 20
Study 14531817 — intervention group
Group type: COMPARATOR
Intervention: Low protein diet (LPD) group (0.6 g/kg body weight/day)
Number of subjects: 20
Study 11036964 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 87
Study 11036964 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 87
Study 11036964 — intervention group
Group type: COMPARATOR
Intervention: Megestrol Acetate (MA)
Number of subjects: 87
Study 9390977 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgravity (microG)
Number of subjects: 4
Study 9390977 — intervention group
Group type: COMPARATOR
Intervention: 1 G
Number of subjects: 4
Study 9390977 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 1.6 G
Number of subjects: 4
Study 9390977 — intervention group
Group type: COMPARATOR
Intervention: 1 G and approximately 1.6 G
Number of subjects: 4
Study 8150902 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous goserelin (3.6 mg)
Number of subjects: 100
Study 8150902 — intervention group
Group type: COMPARATOR
Intervention: Intranasal buserelin acetate (200 micrograms; 6 times/day)
Number of subjects: 100
Study 3784304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondialyzed patients with chronic renal failure
Number of subjects: 36
Study 3784304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing maintenance hemodialysis
Number of subjects: 36
Study 3784304 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 36
Study 3784304 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (normal, nondialyzed, hemodialysis)
Number of subjects: 36
Study 30294848 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (100 mL administered through nasointestinal tube once daily for six consecutive days)
Number of subjects: 83
Study 30294848 — intervention group
Group type: COMPARATOR
Intervention: Enemas (administered once daily for six consecutive days)
Number of subjects: 83
Study 30278566 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorillonite powder
Number of subjects: 58
Study 30278566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 58
Study 26498504 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Control Rate (DCR) at 8 weeks
Number of subjects: 263
Study 26498504 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated lactate dehydrogenase
Number of subjects: 263
Study 24660675 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dynamic psychotherapy with relationship work
Number of subjects: 100
Study 24660675 — intervention group
Group type: COMPARATOR
Intervention: Weekly dynamic psychotherapy without relationship work
Number of subjects: 100
Study 22113935 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tool for osteoporotic vertebral fractures (VFs) administered by a nurse in primary care.
Number of subjects: 3200
Study 22113935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening tool or radiographs).
Number of subjects: 3200
Study 19107626 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) supplementation (8 g/day)
Number of subjects: 45
Study 17443036 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID-ET (NSAID plus etizolam 0.5 mg)
Number of subjects: 144
Study 17443036 — intervention group
Group type: COMPARATOR
Intervention: NSAID (mefenamic acid 250 mg)
Number of subjects: 144
Study 16046372 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 injection
Number of subjects: 28
Study 12032191 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg o.d.
Number of subjects: 21
Study 12032191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10188113 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam 0.025 mg/kg
Number of subjects: 45
Study 10188113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8540943 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose infusion at 180 mL/h (9 g/h)
Number of subjects: 0
Study 8540943 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline solution
Number of subjects: 0
Study 2089144 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and cyproheptadine with interactive locomotor training
Number of subjects: 2
Study 516362 — intervention group
Group type: EXPERIMENTAL
Intervention: delta 9-tetrahydrocannabinol (THC)
Number of subjects: 0
Study 516362 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31710398 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alprostadil
Number of subjects: 80
Study 31710398 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous injection
Number of subjects: 80
Study 30206130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) at 2 L/kg/min
Number of subjects: 10
Study 30206130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) at 1 L/kg/min
Number of subjects: 10
Study 30206130 — intervention group
Group type: COMPARATOR
Intervention: Face mask delivery
Number of subjects: 10
Study 27723577 — intervention group
Group type: EXPERIMENTAL
Intervention: DASC (Dense Adaptive Self-Correlation)
Number of subjects: 0
Study 27723577 — intervention group
Group type: EXPERIMENTAL
Intervention: GI-DASC (Geometry-Invariant DASC)
Number of subjects: 0